Direct-acting antiviral agents (DAAs) are highly effective and well tolerated in patients with chronic hepatitis C virus infection, including those with compensated cirrhosis. However, fewer data are available in patients with more advanced liver disease. Our retrospective, noninterventional, national, multicenter study in patients from the Spanish Hepa-C registry investigated the effectiveness and safety of interferon-free DAA regimens in patients with advanced liver disease, including those with decompensated cirrhosis, in routine practice (all currently approved regimens were registered). Patients transplanted during treatment or within 12 weeks of completing treatment were excluded. Among 843 patients with cirrhosis (Child-Turcotte-Pugh [CTP] class A, n 5 564; CTP class B/C, n 5 175), 90% achieved sustained virologic response 12 weeks after treatment (SVR12). Significant differences in SVR12 and relapse rates were observed between CTP class A and CTP class B/C patients (94% versus 78%, and 4% versus 14%, respectively; both P < 0.001). Serious adverse events (SAEs) were more common in CTP class B/C versus CTP class A patients (50% versus 12%, respectively; P < 0.001). Incident decompensation was the most common serious adverse event (7% overall). Death rate during the study period was 16/843 (2%), significantly higher among CTP class B/C versus CTP class A patients (6.4% versus 0.9%; P < 0.001). Baseline Model for End-Stage Liver Disease (MELD) score alone (cut-off 18) was the best predictor of survival. Conclusion: Patients with decompensated cirrhosis receiving DAAs present lower response rates and experience more SAEs. In this setting, a MELD score 18 may help clinicians to identify those patients with a higher risk of complications and to individualize treatment decisions. (HEPATOLOGY 2017;65:1810-1822.
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A n estimated 130-150 million people worldwide are chronically infected with hepatitis C virus (HCV).
(1) Cirrhosis develops in 10%-15% of patients with chronic HCV infection within 20 years, (2) and in these individuals the risk of progression to hepatic decompensation and hepatocellular carcinoma (HCC) is substantial and can occur relatively rapidly. (3) (4) (5) These complications mean that chronic HCV infection-related advanced liver disease has become the most common indication for liver transplantation in the Western world and in Japan. (6) The availability of potent, well-tolerated direct-acting antiviral agents (DAAs), which can be administered in short, interferon (IFN)-free regimens, has improved the management of patients with HCV infection dramatically. Clinical studies have demonstrated rates of sustained virologic response (SVR) of over 90% with these regimens, even in patients with compensated cirrhosis. (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) Lower virologic response rates have been reported in patients with advanced liver disease and decompensated cirrhosis. (17) (18) (19) (20) (21) Achievement of SVR with IFN-based regimens in patients with cirrhosis decreases hepatic decompensation, HCC, and liver-related mortality. (22) (23) (24) (25) However, the beneficial effects of SVR in patients with more advanced disease and decompensated cirrhosis are unknown, because IFN is contraindicated in these patients. Studies suggest that improvements in liver function in these patients might be achievable with IFN-free DAA regimens. In the SOLAR studies, patients with advanced liver disease treated with ledipasvir/sofosbuvir (LDV/SOF) who achieved SVR demonstrated discrete improvements in Model for End-Stage Liver Disease (MELD) scores, (17, 18) and similar results have been reported with sofosbuvir/velpatasvir (SOF/VEL) (27) as well as in patients with decompensated cirrhosis treated in an expanded access program. (20) However, although treatment with new regimens may be attractive, potential benefits still need to be balanced against the risk of adverse events (AEs). Safety data in patients with very advanced and decompensated cirrhosis are limited, but there have been reports of liver toxicity and lactic acidosis in patients receiving DAAs. (28) Although causality has not been proven, such observations have raised concerns. (28) (29) (30) Further data, particularly those from the real-world setting are crucial to help guide treatment decisions in this complex patient population. We investigated the effectiveness and safety of DAA regimens in patients with advanced cirrhosis, including decompensated cirrhosis, managed in routine clinical practice in Spain.
Materials and Methods
This was a retrospective, noninterventional, national, multicenter study of patients included in the Spanish Hepa-C registry. Hepa-C is a collaborative, monitored national registry of patients with chronic HCV infection managed in routine clinical practice. Informed consent is obtained in writing from all patients in the registry. Patients from clinical trials are excluded. The registry is governed by the Spanish Association for the Study of the Liver (AEEH) and the Networked Biomedical Research Centre for the Study of the Liver and Digestive Diseases (CIBERehd). Monitoring is a key element of the database, ensuring accuracy of data and minimization of bias. Assistance with data entry and technical support was provided, and all entered data were reviewed monthly for inconsistencies.
Inclusion criteria were 1) treatment with an IFNfree DAA regimen and 2) presence of cirrhosis according to liver biopsy and/or transient elastography (FibroScan) and/or clinical criteria (ultrasound evidence, previous/current decompensation and/or esophageal/gastric varices). Patients were eligible if they were not a candidate for liver transplantation or if they had been listed for, but did not undergo, transplantation during treatment or within 12 weeks of completing treatment. These criteria allowed improvement of liver function attributable to DAA treatment to be assessed without the influence of liver transplantation. The study period was defined as treatment duration (12 or 24 weeks) plus 12 weeks posttreatment. The study inclusion period was April 8, 2013 
OUTCOMES
Effectiveness assessment included: sustained virologic response 12 weeks after treatment (SVR12; negative HCV RNA at week 12 posttreatment); relapse (positive HCV RNA after treatment when previously negative); virologic breakthrough (positive HCV RNA during treatment when previously negative). All HCV RNA measurements were made using highly sensitive quantitative polymerase chain reaction assays. The ongoing nature of Hepa-C precluded an intention to treat (ITT) analysis due to missing outcomes among the 170 patients who had not reached the end of the study period at the time of the effectiveness assessment. However, the effectiveness analysis included patients who completed the study (per protocol) as well as those who discontinued or died. Because all patients in the analysis received at least one dose of medication, we defined our effectiveness analysis as modified ITT (mITT). Safety assessments included death (date, cause) and serious adverse events (SAEs; events that were lifethreatening, led to hospital admission or prolonged an existing hospital stay, resulted in death, or were judged as serious by the treating physician). Hepatic decompensation was defined as the presence of variceal hemorrhage, ascites, and/or portosystemic (hepatic) encephalopathy, and was considered a serious adverse event (SAE). All safety assessments were performed on the total patient cohort.
STATISTICAL ANALYSIS
Descriptive statistics were used for quantitative variables (number, median, minimum, maximum) and categorical variables (relative frequencies). Confidence intervals at the 95% level were calculated where required. For hypothesis contrasts, a Fisher's exact test was performed with categorical variables and a MannWhitney U test was performed for quantitative variables (unpaired groups).
Multivariable logistic regression models were developed to identify predictive factors for AEs and death, using clinically meaningful covariables with statistical significance in the univariate analysis or P < 0.1 and no suspicion of colinearity. Area under the curve of the receiving operator characteristic (AUROC) and the Hosmer-Lemeshow goodness of fit test were used to assess calibration of the models. Survival analysis was performed with Cox regression and Kaplan-Meier analyses. Log-rank tests were used to assess statistically significant differences between Kaplan-Meier curves. Predictive models were transformed into nomograms to obtain an easy-to-use and visual tool. Two-tailed P < 0.05 was considered statistically significant. Stata/ IC version 14.1 (StataCorp, College Station, TX) was used for all calculations. Nomolog and Nomocox programs were used to build the nomograms on Stata software.
(31)
Results

PATIENT CHARACTERISTICS
A total of 843 patients with cirrhosis from 26 Spanish centers, including 24 academic centers, were included in the analysis (CTP class A, n 5 564; CTP class B, n 5 162; CTP class C, n 5 13). Overall, only 7% of patients were listed for liver transplantation. Out of 843 patients, 739 (88%) had baseline CTP class available and 741 (88%) had baseline MELD score available. Given that first decompensation event is clinically very relevant, patients were classified as compensated (CTP class A patients) or decompensated (CTP class B/C patients). Compared with CTP class A patients, CTP class B/C patients showed significantly poorer liver function (lower median albumin level, higher proportion of patients with albumin <3.5 g/ dL, higher bilirubin) and significantly more severe liver disease (higher median MELD score, lower platelet counts) (Table 1 ). There was no significant difference in the proportion of patients with HCC. CTP class B/C patients included a significantly lower proportion of patients with HCV RNA >10 6 copies/mL. In patients with available data (n 5 740), 26 (3.5%) had baseline MELD scores 18 (Supporting Table 1 ).
TREATMENT
All DAA treatment regimens approved for use in patients with HCV infection in the European Union during the study period were represented in the patient cohort (Fig. 1) . The most commonly used regimens were SOF 1 simeprevir (SMV, 45%) and SOF 1 nonstructural protein 5A (NS5A) inhibitor (daclatasvir, 22%; LDV, 16%), with SMV being used less frequently in CTP class B/C patients in accordance with treatment recommendations at the time of the study ( Table 2 ). The extent of RBV use varied between treatment regimens and was also significantly less common in CTP class B/C patients. More patients were treated for 12 weeks (73%) than for 24 weeks (25%). Treatment was interrupted in 2% of patients. Significantly more CTP class A patients were treated for 12 weeks versus 24 weeks (84% versus 16%, respectively; P < 0.001) and significantly more CTP class B/C patients received 24 weeks versus 12 weeks of treatment (54% versus 46%, respectively; P < 0.001).
EFFECTIVENESS ANALYSIS
Overall, 673 patients had effectiveness data available. Of these 673 patients, 604 (90%) achieved SVR12 (mITT analysis). Among those patients who failed to achieve SVR, 16 (2%) died, nine (1%) experienced virologic breakthrough, and 45 (7%) relapsed. There were significant differences in SVR12 between CTP class A and CTP class B/C patients (94% versus 78%, respectively; P < 0.001) (Fig. 2A) . The rate of relapse was significantly higher in CTP class B/C versus CTP class A patients (14% versus 4%, respectively; P < 0.001) (Fig. 2B) . A higher proportion of CTP class B/C patients were infected with genotype 3, which is particularly difficult to treat. However, excluding these patients did not affect overall SVR12 rates (CTP class A, 94% versus CTP class B/C, 78%; P < 0.001) or rates of relapse (CTP class A, 4% versus CTP class B/C, 13%; P 5 0.001). No significant differences were observed between the two principal treatment regimens (Table 2) . SVR12 rates according to genotype are presented in Supporting Figure 1 .
Regardless of treatment duration, the addition of RBV resulted in higher SVR12 rates in CTP class A patients (SVR12 96% with RBV versus 90% without RBV; P 5 0.019). No significant difference was observed in CTP class B/C patients (SVR12 81% with RBV versus 74% without RBV; P 5 0.427). Similar results were found in patients treated for 12 weeks (data not shown), but no associations were found among those treated for 24 weeks. Further analyses were limited by insufficient patients being treated for 24 weeks and the infrequent use of RBV in CTP class B/C patients.
SAFETY ANALYSIS
SAEs were reported for 171/843 patients (20%), with the majority of SAEs (85%) occurring during treatment. The most commonly reported SAEs were incident decompensation (55/843; 7%), anemia requiring transfusion (21/843; 2%) and grade 3/4 infection (20/843; 2%). No significant differences were observed between the two principal treatment regimens (Table  2) . CTP class B/C patients experienced significantly more SAEs compared with CTP class A patients overall (50% versus 12%, respectively; P < 0.001) and for each of the most commonly reported SAEs (incident decompensation, 16% versus 4%; anemia requiring transfusion, 8% versus 2%; grade 3/4 infection, 8% versus 1%; all P < 0.001). We further assessed the impact of RBV use on anemia and the need for transfusion. Overall, incident anemia of any grade (anemia in patients with no anemia at baseline or grade increase in patients with anemia at baseline) was high during the study period (174/843; 21%) and was related to RBV use in both CTP groups (CTP class A: 19% with RBV versus 8% without RBV, P 5 0.002; CTP class B/C: 42% with RBV versus 24% without RBV, P 5 0.016). However, the infrequent need for transfusion during the study period was not significantly associated with RBV use, irrespective of CTP group (A versus B/C) (P > 0.05). No discontinuations due to SAEs, including anemia requiring transfusion, were reported.
Our study was not designed to evaluate recurrent and incident HCC, and no specific protocol was established. However, recent studies (32, 33) prompted an additional post hoc safety analysis. In our cohort, 58 patients had a previous diagnosis of HCC. Among 45 of these patients who had a complete response prior to commencing DAA therapy, seven (16%) experienced HCC recurrence within 1 year. Incident HCC was reported in 23 patients (3%) (Supporting Table 2 ).
Sixteen patients (2%) died during the course of the study, 13 from liver-related causes, including two from HCC (Supporting Table 3 ). Thirteen deaths (81%) occurred during treatment. The mortality rate was higher in CTP class B/C patients compared with CTP class A patients (6.4% versus 0.9%; P < 0.001).
PREDICTION OF SAEs DURING THE STUDY PERIOD
In univariate analysis, albumin (continuous and <3.5 g/dL), bilirubin, creatinine, international normalized ratio, prothrombin activity, and platelet count (continuous and <100,000/mm 3 ) at baseline were significantly associated with development of SAEs (P 5 0.022 for creatinine; P < 0.001 for all others). Baseline MELD score and CTP group (A versus B/C) also revealed a significant association with SAEs (P < 0.001 for both). Regimen choice, liver stiffness, diabetes or cardiovascular disease at baseline, age, and sex were not significant on univariate analysis (P > 0.05). All significant laboratory parameters on univariate analysis were also independently associated with SAEs on multivariate analysis, with the exception of international normalized ratio (P 5 0.559). Baseline MELD score and CTP group (class A versus class B/C) also showed a significant association with SAEs on multivariate analysis (P < 0.001 for both). In fact, MELD score alone performed well as a predictor of SAE occurrence during the study period using logistic regression (odds ratio [OR], 1.46; 95% CI, 1.36-1.56; P < 0.001) (AUROC, 0.8302; Fig. 3A ) (P 5 0.029 for Hosmer-Lemeshow goodness of fit test). When fitting MELD, albumin, and platelets in a model, the predictive value was very similar (AUROC 0.8325) (P 5 0.056 for Hosmer-Lemeshow goodness of fit test). Thus, given its widespread use, MELD score alone seemed a practical and simple predictor for SAEs during the study period (details of the multivariant model and associated nomogram for prediction of SAEs are presented in Supporting Table 4 and Supporting Figs. 2 and 3 ).
PREDICTION OF DEATH AND SURVIVAL DURING THE STUDY PERIOD
On univariate analysis, significant factors related to death over the study period were the same as those for the development of SAEs, with the exception of platelet levels (trend toward significance, P 5 0.086). Among them, MELD score was found to perform well as a predictor of death during the study period using logistic regression (OR, 1.30; 95% CI, 1.18-1.43; P < 0.001; AUROC, 0.8872; 3. Prediction models of SAEs and deaths during the study period: performance of MELD. Multivariable logistic regression models were used to identify predictive factors for adverse events and death using covariables that achieved statistical significance in the univariate analysis, were clinically meaningful, and had no suspicion of colinearity. However, MELD score alone performed well as a predictor and was easy to use. (A) MELD score was fitted into a logistic regression model for prediction of SAEs with a good AUROC. (B) MELD score was fitted into a logistic regression model for prediction of deaths during the study period, also yielding a good AUROC. The predictive performance of a MELD score 18 is indicated.
constructed based on the data from our cohort applying MELD score for the prediction of survival in routine practice (Supporting Fig. 4 ). Specificity and sensitivity were calculated for various cut-off values of MELD score to identify a value that would be clinically useful to predict which patients were most likely to survive during the study period (Supporting Table 5 ). Because patients with shorter life expectancy may be less suitable candidates for treatment, we chose a conservative approach to defining the MELD threshold, assuming that, on balance, most patients would be likely to benefit from antiviral treatment. A MELD score of 18 was therefore selected as a cutoff value because of its very high specificity (97%), despite its low sensitivity (32%). A MELD score of 18 differentiated two populations according to likelihood of survival during the study period, with significantly greater survival in the MELD <18 population (Fig. 4A) . Mortality rate was not dependent on treatment duration (Fig. 4B) . In fact, when testing for proportionality in Further analyses aimed at improving the predictive power of MELD alone by adding albumin and platelets were unsuccessful. The multivariable regression analysis of death produced the same AUROC as MELD alone (Supporting Table 4 and Supporting Figure 4) . Multivariable Cox regression analysis showed similar results (data not shown). Baseline MELD score was definitely an accurate and simple predictor of mortality and survival during the study period.
CHANGE IN LIVER FUNCTION AFTER TREATMENT
Change in MELD score from baseline was assessed at 12 weeks post-treatment. In all, 471 patients had MELD data available at both time points. Overall, 36% showed improvements in MELD score, 31% had no change and 33% worsened (Fig. 5A) . In most cases, changes in MELD scores were modest, with approximately 90% of patients showing a change of only 1-2 points overall.
In univariate analysis, improvement in MELD score from baseline was associated with the severity of liver disease (Fig. 5 B,C) ; CTP class B/C patients versus CTP class A (56% versus 31%; P<0.001), baseline MELD (continuous [P < 0.001] and 18 [87% versus 35%; P 5 0.005]), and baseline platelets (continuous and <100,000/mm 3 ; P < 0.001 for both). There was no association with transient elastography, age, achievement of SVR, or relapse. CTP (OR, 2.36; 95% CI, 1.14-3.94; P 5 0.001), baseline MELD score (OR, 1.26; 95% CI, 1.13-1.39; P < 0.001), and platelets <100,000/mm 3 (OR, 1.55; 95% CI, 1.02-2.37; P 5 0.041) remained significantly associated with improvements in MELD on multivariate analysis.
Discussion
In agreement with a recent review, (34) in our cohort of patients with advanced liver disease, treatment with DAAs in routine clinical practice was highly effective, achieving an SVR12 of 90% (mITT), and was generally well tolerated. However, the presence of decompensated cirrhosis (CTP class B/C) at baseline was associated with lower rates of virologic response compared with patients with less advanced cirrhosis (CTP class A). Baseline CTP class B/C was also associated with higher rates of relapse, SAEs, and death during the study period compared with CTP class A. Current treatment guidelines recommend prioritization of treatment for patients with advanced fibrosis or cirrhosis (METAVIR score F3 to F4) and urgent treatment of patients with decompensated cirrhosis with an IFN-free regimen. (35) Data from clinical trials and real-life cohorts have shown these regimens to be well tolerated and effective in patients with compensated cirrhosis, achieving rates of SVR above 90%. (12, 16, 36, 37) The overall rate of relapse in the current study was high compared with that reported for DAA regimens in clinical trials, and was largely accounted for by the high relapse rate in CTP class B/C patients. In the SOLAR-2 study, 9/10 patients with advanced liver disease who relapsed following treatment with LDV/ SOF plus RBV had decompensated cirrhosis. (18) The relapse rate in CTP class B/C patients in our study was similar to that reported in a real-world cohort of patients with decompensated cirrhosis treated with DAAs (20) and is clearly greater than in compensated patients. The explanation for this seems multifactorial; lower drug delivery as well as impaired drug metabolism and immune responses have been proposed to account for a poorer response to HCV treatment in patients with cirrhosis. (38) These alterations may be more apparent in patients with more advanced liver disease. Adding RBV seemed useful to improve SVR rates among CTP class A patients treated for 12 weeks without an increased need of transfusion, although no firm conclusions could be reached regarding CTP class B/C patients or longer treatment durations.
There is substantial evidence that achievement of SVR with IFN-based regimens is associated with improvements in fibrosis and liver function (CTP and MELD scores) and a lower incidence of clinical events, (35) including HCC and death. (5, 24, 39) However, equivalent evidence in patients with advanced liver disease, particularly decompensated cirrhosis, has been limited by the contraindication of IFN in this population. Recent studies with IFN-free regimens have reported high rates of virologic response in patients with advanced liver disease and an associated improvement in liver function, evidenced by a decrease in MELD score. (17, 20, 27, 40) In the SOLAR-1 study, patients with advanced liver disease treated with LDV/ SOF 1 RBV, who went on to achieve SVR, showed early improvements in MELD (week 4 of treatment), and similar results were seen with SOF/VEL 6 RBV in the ASTRAL-4 study, suggesting that viral clearance can improve hepatic function rapidly, likely due to attenuation of injury and inflammation caused by HCV infection. (17) In a real-world study of patients with decompensated cirrhosis, DAAs were also associated with improvements in MELD score over 6 months compared with worsening in untreated patients. (20) In this study, although SVR did not predict change in MELD score, fewer patients who achieved SVR had a marked worsening in MELD. (20) In a later study, further follow-up demonstrated an uncertain improvement in MELD score from 6 to 15 months after treatment. (41) In our cohort, treatment was associated with improvements in MELD scores, particularly in CTP class B/C patients and in patients with baseline MELD 18, regardless of SVR or relapse. However, in our study, as well as those of others, variations in MELD were limited, with 90% of patients having a maximum change of 2 points. This magnitude of change is of doubtful clinical relevance, particularly in patients with higher MELD scores. A recent study of IFN-treated patients with cirrhosis showed that only those in whom portal pressures decreased to <10 mm Hg after achieving SVR were at reduced risk of decompensation over a median time of 5 years. (26) Similar benefits may be achieved with IFN-free regimens. In two recent studies including CTP class A and B patients treated with DAAs, clinically meaningful amelioration in hepatic venous pressure gradient 24 and 48 weeks after treatment was demonstrated. (42, 43) However, a reduction of 10% was less likely among patients with the most advanced disease. (43) In addition, some increases in pulmonary arterial pressure and pulmonary vascular resistance were also reported. The future consequences of this are unknown. Thus, assessment of liver function early during treatment or up to 15 months after treatment seems to be insufficient to draw firm conclusions on the natural history of liver disease. However, early small improvements in liver function and hemodynamics seem to be apparent. The maximum follow-up in our study was 36 weeks, therefore the focus was on short-term events. Long-term follow-up of patients with decompensated cirrhosis treated with DAAs is needed to assess enduring benefits, such as reversibility of liver failure, decreased need for liver transplantation, and reductions in the incidence of HCC and liver-related mortality as has been observed, for the most part, with IFN-based regimens. (39) The incidence of SAEs in our cohort was high compared with clinical trials in patients with cirrhosis, (12, 15, 21, 36) but in line with other studies of DAAs in patients with advanced liver disease and/or decompensated cirrhosis. (17, 18, 27) As would be expected, and as reported previously, (17, 18) decompensation was the most common SAE in our study. Safety was poorest in CTP class B/C patients, with half of all patients experiencing an SAE compared with 12% of CTP class A patients. Although RBV use did not have any influence, treatment choice may still have had an impact on the SAE profile of our cohort. Although causality of decompensation with DAAs is difficult to establish on a background of advanced liver disease, hepatic decompensation and hepatic failure, including fatal cases, have been reported after marketing in patients treated with SMV in combination with peginterferon alfa and RBV and in combination with SOF. (30, 44, 45) A significant proportion of CTP class B/C patients in our cohort received treatment with regimens including SMV, which is not recommended by current prescribing guidelines. (44) However, at the time of treatment, it was the only option available for many patients and no significant differences in AEs or SAEs between patients receiving SOF 1 SMV and those receiving SOF 1 an NS5A inhibitor were apparent ( Table 2) . Decompensation has also been reported in patients with cirrhosis who were treated with ombitasvir/paritaprevir/ritonavir 1 dasabuvir and has led to recommendations for additional monitoring by health authorities. (46) However, this regimen was not associated with SAEs among CTP class B/C patients in our cohort.
In our analysis, baseline factors associated with poorer liver function were significantly associated with SAEs. A study of patients with compensated and decompensated cirrhosis treated with SMV 1 SOF reported more AEs in CTP class B/C patients; however, adverse safety outcomes were common in matched untreated controls, suggesting that safety events reflected the natural history of cirrhosis and were not related to treatment. (47) Despite this, the higher rates of SAEs in CTP class B/C patients reported in our study and others, together with emerging postmarketing data, emphasize the need for careful assessment of risks and benefits of DAA therapy in patients with advanced liver disease and for close monitoring, particularly those with a greater MELD score. Interpretation of the HCC findings demands extreme caution given that our study was not designed specifically to assess this topic and no specific protocol was in place for HCC diagnosis or surveillance.
In addition to a higher rate of SAEs, significantly more CTP class B/C than CTP class A patients died during the course of the study. In regression analysis, a baseline MELD score of 18 was found to be predictive of death over the study period with high specificity (97%). No additional baseline factors (albumin level and platelet count) improved the predictive performance of the model. Given that MELD score is regularly used in routine clinical practice and was also highly predictive of SAEs, we would recommend using the MELD score alone as a predictive factor. Even though most patients in our study were not candidates for liver transplantation, our results may be considered when managing patients on the transplant waiting list. Although MELD 18 is potentially useful for clinical decision making in all patients with advanced liver disease, it may have particular relevance for determining patients in whom HCV treatment pre-or posttransplantation would be safer. A major concern in liver transplant candidates is that attainment of SVR may not be associated with sufficient improvement in liver function to allow patients to live well without transplantation, or to reduce the risk of HCC. (6) In two recent studies, some listed patients on IFN-free treatment could be delisted. (48, 49) It is noticeable that patients with baseline MELD 16-20 had a higher probability of being delisted than those with MELD >20 in one study, (48) and that no patient with MELD >18 was delisted in the other study. (49) These observations seem to be in accordance with our study and suggest that, if treated, patients with high MELD scores may be deprioritized on the transplant list owing to a discrete MELD reduction without real clinical improvement. Given the efficacy of DAA therapy in liver transplant recipients, some have argued that it may be better for patients with decompensated cirrhosis awaiting a liver transplant to be treated for HCV posttransplantation. (6) Although there is a clear need for predictors of clinical response and long-term outcomes after SVR, the ability to predict those patients with decompensated cirrhosis who may not tolerate or survive treatment may also help to decide whether to treat pre-or posttransplantation. Nevertheless, those decompensated patients who are not candidates for liver transplantation may have a greater need of treatment than the listed patients, given that they have no alternative. (6) The limitations of the current study are those inherent to its retrospective, observational design, including lack of a control group. Because treatment regimens were not randomized, it is possible that treatment choice may have influenced outcomes, and thus interpretation. We cannot exclude the possibility of influence on the predictive value of our models, but any effect is likely to be minor. The short follow-up does not allow for evaluation of long-term effects of treatment but does focus on a highly clinically relevant period. Finally, the inclusion of only 13 CTP class C patients in our study limits its applicability in this subpopulation compared with CTP class B patients. However, our findings using MELD score suggest that a direct correlation exists between the severity of liver disease and unfavorable outcomes.
Our study adds to the increasing body of evidence supporting the effectiveness of treatment with secondgeneration DAAs in patients with advanced HCVrelated liver disease. However, it also emphasizes the potential for SAEs and death in patients with decompensated cirrhosis treated with these regimens. It is therefore important that clinicians consider the potential risks and benefits of treating patients with latestage liver disease on a case-by-case basis and have open and honest discussions with such patients regarding their best course of management.
